Biomedical Sciences

Quillen College of Medicine

Biomedical Sciences

Qian Xie

Qian Xie

Associate Professor

 

Additional Contact Information: 


Department of BioMedical Sciences
Quillen College of Medicine 
Stanton-Gerber Hall, Bldg.178 
P.O. Box 70582 
Office A026, Lab A021-022 
Phone: 423-439-5332 
Email: xieq01@etsu.edu

EDUCATION/PROFESSIONAL EXPERIENCE

Dr. Xie received her M.D. degree from Fudan University Shanghai Medical College in China. She also received her Ph.D. degree in Oncology at a later time from the same university. After that, she became a postdoctoral fellow in Molecular Oncology at Van Andel Research Institute, Michigan, where she also held positions as Senior Research Scientist and Research Assistant Professor. Dr. Xie joined East Tennessee State University Quillen College of Medicine in 2016. She is current a tenured Associated Professor at Department of Biomedical Science. She is also the Course Director for Biomedical Sciences Core Module 3 (BMS-3) at ETSU Graduate Program. 

RESEARCH/TEACHING INTERESTS

The success of molecular targeted therapy in cancer depends on knowledge of essential pathways that contribute to oncogenesis and the molecular targets that control pathway activity. My lab studies molecular oncology and targeted therapy with a focus on developing therapeutic strategies for targeting MET receptor tyrosine kinases (RTK) in glioblastoma and hepatocellular carcinoma. Previous work from this lab has elucidated molecular mechanisms of MET-targeting small molecule inhibitors, neutralizing antibodies as anti-cancer therapeutics. Patient-derived xenograft models and transgenic mouse models have been established for evaluating the therapeutic efficacy. Our recent research interests have been to develop MET-targeting chimeric antigen receptor (MET-CAR) T cells for treating MET-positive tumors and to understand the molecular mechanisms of therapeutic responses. 

Research Interests:

  1. Develop MET-CAR T cell therapy for targeting MET-positive tumors 
  2. Understand the molecular mechanisms driving MET-CAR T cell therapeutic responses. 
  3. Identify immunotherapeutic strategies to accelerate MET-targeted therapy. 

SELECTED PUBLICATIONS

  1. Qin A*, Musket A*, Hilton B, Preiszner J, Krenciute G, Berens ME, Ying M, Musich PR, Xie Q.  Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models. J Transl Med, 23(1):460, 2025 
  2. Qin A, Qin Y, Lee J, Musket A, Yao ZQ, Krenciute G, Marincola FM, Musich PR, Xie Q. Tyrosine kinase signaling independent MET targeting with CAR T cells. J Transl Med. 21:682, 2023.
  3. Qin A, Musket A, Musich PR, Schweitzer JB, Xie Q. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matters? Neuro-Oncology Advance. 3(1): vdab133, 2021
  4. Land CA, Musich PR, Haydar D, Krenciute G, Xie Q. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Charging the T Cells to Fight. J Transl Med 18: 428, 2020
  5. Qin Y, Musket A*, Kou J, Preiszner J, Tschida BR, Qin A, Land CA, Staal B, Kang L, Tanner K, Jiang Y, Schweitzer JB, Largaespada, DL, and Xie Q. Overexpression of HGF/MET Axis along with p53 Inhibition Induces de novo Glioma Formation in Mice. Neuro-Oncology Advance. 2(1): vdaa067. 2020
  6. Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. J Transl Med. 12;16(1):253, 2018. 
  7. Xie Q*, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro-Oncology. 16;12:1575-1584, 2014 [*Corresponding author]
  8. Xie Q*, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su YL, Essenburg C, Kaufman D, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, and Vande Woude GF*. HGF-autocrine Activation Predicts Sensitivity to MET Inhibition in Glioblastoma. PNAS. 109(2):570-5, 2012 [*= co-corresponding authors]

Textbook:

  1. Shinomiya N, Kataoka H, Xie Q. Regulation of signal transduction in human cell research. Singapore: Springer Nature; 2018

Book Chapters:

  1. Thewke D, Kou J, Fulmer M, Xie Q. The HGF/MET signaling and therapeutics in cancer. In: Regulation of signal transduction in human cell research. edn. Edited by Shinomiya N, Kataoka H, Xie Q. Singapore: Springer Nature; 2018: 155-182
  2. Shinomiya N, Xie Q, Vande Woude G: Met activation and carcinogenesis. In: Regulation of signal transduction in human cell research. edn. Edited by Shinomiya N, Kataoka H, Xie Q. Singapore Springer Nature 2018: 129-154